Neurocrine Biosciences Inc
NBIXNeurocrine Biosciences Inc (NBIX) is a biopharmaceutical company focused on the development and commercialization of treatments for neurological and endocrine disorders. Founded in 1992, the company specializes in innovative therapies for conditions such as Parkinson's disease, Tourette syndrome, and endometriosis, leveraging expertise in neuroscience and endocrine biology.
Company News
Neurocrine Biosciences announced that its Phase 3 KINECT-DCP study evaluating valbenazine for dyskinetic cerebral palsy failed to meet primary and key secondary endpoints. The drug did not show improvement in chorea as intended. Despite the miss, analysts at William Blair believe the setback has limited impact on the company's valuation and inves...
Connecticut-based fund Braidwell established a new $50.8 million stake in Acadia Pharmaceuticals, representing 2.1% of its reportable U.S. equity assets, as the company shows strong quarterly performance and potential for growth in neurological disorder treatments.
Nxera Pharma reported increased revenues from PIVLAZ® and QUVIVIQ® in Japan, progress in partnered programs including Neurocrine's Phase 3 trial, and launched a new proprietary pipeline targeting obesity and weight management.
Neurocrine Biosciences reported strong Q2 2025 financial results, with revenue of $687.5 million, exceeding analyst expectations. The company saw significant growth from INGREZZA and a successful launch of CRENESSITY, while continuing to invest in its drug pipeline and research and development.
Voyager Therapeutics expanded its Alzheimer's disease franchise by introducing a new gene therapy program targeting APOE, complementing existing tau and amyloid assets. The program aims to reduce APOE4 variant expression while delivering the protective APOE2 variant using an innovative IV-delivered TRACER capsid.
